Untitled Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): April 16,
2019
AMERICAN BIO MEDICA CORPORATION
(Exact
name of registrant as specified in this charter)
New
York
|
0-28666
|
14-1702188
|
(State or
other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
122 Smith Road,
Kinderhook, NY
|
12106
|
(Address of
principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
ITEM
2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On
April 16, 2019, American Bio Medica Corporation (the "Company")
announced financial results for the quarter and year ended December
31, 2018. A copy of the press release announcing the
Company’s results (the "Press Release") is attached hereto as
Exhibit 99.1 and is incorporated by reference in this Item 2.02.
The Press Release is available on the Company’s website. The
information provided in Item 2.02 of this report, including
Exhibit 99.1, shall be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended.
ITEM
9.01
FINANCIAL STATEMENTS AND EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMERICAN BIO MEDICA
CORPORATION (Registrant)
|
|
|
|
|
|
Date:
April
16, 2019
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
Melissa A.
Waterhouse
|
|
|
|
Chief Executive
Officer (Principal Executive Officer)
Principal
Financial Officer
|
|